HEPLISAV-B achieved preliminary net product revenue of $268M for the full year 2024, an increase of 26% compared to $213M for the full year 2023. FY24 revenue consensus $276.94M
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
